Kintor Pharmaceutical Ltd

Company Profile

• Business description

  Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-B (GT90008), and AR-PROTAC Compound (GT20029). The company operates in a single segment focusing on the research and development of medical products.

• Contact

  No. 20 Songbei Road
  Suzhou Industrial Park
  Jiangsu
  Suzhou215123
  CHN

  T: +86 51262639909

  https://www.kintor.com.cn

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2025

  Employees

  168